Table 3 Adverse events of 85 NSCLC patients with EGFR mutations treated with ICIs
Adverse Events | Total | ICIs + Chemo | ICIs + Anti-VEGFR | ICIs + Chemo + Anti-VEGFR | |||
|---|---|---|---|---|---|---|---|
N (%) | Any grade | Grade 3 | Any grade | Grade 3 | Any grade | Grade 3 | |
Fatigue | 8 (9.4%) | 5 (11.6%) | 0 (0%) | 2 (8.7%) | 0 (0%) | 1 (5.3%) | 0 (0%) |
Nausea/vomiting | 26 (30.6%) | 12 (27.9%) | 0 (0%) | 5 (21.7%) | 0 (0%) | 9 (47.4%) | 0 (0%) |
Constipation | 5 (5.9%) | 1 (2.3%) | 0 (0%) | 2 (8.7%) | 0 (0%) | 2 (10.5%) | 0 (0%) |
Hypertension | 27 (31.8%) | 5 (11.6%) | 0 (0%) | 14 (60.9%) | 0 (0%) | 8 (42.1%) | 0 (0%) |
Rash | 7 (8.2%) | 2 (4.7%) | 0 (0%) | 4 (17.4%) | 0 (0%) | 1 (5.3%) | 0 (0%) |
Leukopenia | 31 (36.5%) | 19 (44.2%) | 2 (4.7%) | 6 (26.1%) | 0 (0%) | 6 (31.6%) | 1 (5.3%) |
Neutropenia | 24 (28.2%) | 16 (37.2%) | 3 (7.0%) | 3 (13.0%) | 0 (0%) | 5 (26.3%) | 1 (5.3%) |
Thrombocytopenia | 12 (14.1%) | 6 (14.0%) | 0 (0%) | 4 (17.4%) | 1 (4.3%) | 2 (10.5%) | 0 (0%) |
Anaemia | 44 (51.8%) | 27 (62.8%) | 1 (2.3%) | 6 (26.1%) | 0 (0%) | 11 (57.9%) | 1 (5.3%) |
ALT increase | 12 (14.1%) | 6 (14.0%) | 0 (0%) | 3 (13.0%) | 0 (0%) | 3 (15.8%) | 1 (5.3%) |
AST increase | 12 (14.1%) | 7 (16.3%) | 0 (0%) | 3 (13.0%) | 0 (0%) | 2 (10.5%) | 1 (5.3%) |
Creatinine increase | 11 (12.9%) | 4 (9.3%) | 0 (0%) | 5 (21.7%) | 0 (0%) | 2 (10.5%) | 0 (0%) |
Thyroid dysfunction | 26 (30.6%) | 7 (16.3%) | 0 (0%) | 10 (43.5%) | 0 (0%) | 9 (47.4%) | 0 (0%) |
Proteinuria | 6 (7.1%) | 4 (9.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (10.5%) | 0 (0%) |
Pneumonia | 1 (1.2%) | 1 (2.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |